Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study

Graham, 2004, Oxaliplatin, Nat. Rev. Drug Discov., 3, 11, 10.1038/nrd1287 Folprecht, 2007, Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer, Cancer Treat. Res., 134, 425 André, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J. Clin. Oncol., 27, 3109, 10.1200/JCO.2008.20.6771 Haller, 2011, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J. Clin. Oncol., 29, 1465, 10.1200/JCO.2010.33.6297 Xu, 2016, Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis, OncoTargets Ther., 9, 4833, 10.2147/OTT.S104981 Raymond, 1998, Oxaliplatin: mechanism of action and antineoplastic activity, Semin. Oncol., 25, 4 Saif, 2005, Management of oxaliplatin-induced peripheral neuropathy, Ther. Clin. Risk Manag., 1, 249 Mols, 2014, Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review, Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer., 22, 2261 Stefansson, 2016, Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life, Acta Oncol, 0, 1 Saad, 2016, Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy, J. Neurooncol., 127, 373, 10.1007/s11060-015-2049-x Kim, 2017, Duloxetine protects against oxaliplatin-induced neuropathic pain and spinal neuron hyperexcitability in rodents, Int. J. Mol. Sci., 18, 10.3390/ijms18122626 Bradley, 2014, Efficacité d'un tableau d'ajustement de l'oxaliplatine selon le grade de neuropathie à l'Hôtel-Dieu de Québec, Pharmactuel., 47 Common terminology criteria for adverse events (CTCAE) version 4.0, Natl. Cancer Inst. (n.d.). http://www.cancer.gov/ (Accessed 29 August 2016). Attal, 2009, Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study, Pain, 144, 245, 10.1016/j.pain.2009.03.024 Bouhassira, 2004, Development and validation of the neuropathic pain symptom inventory, Pain, 108, 248, 10.1016/j.pain.2003.12.024 Shy, 2003, Quantitative sensory testing report of the therapeutics and technology assessment subcommittee of the American academy of neurology, Neurology, 60, 898, 10.1212/01.WNL.0000058546.16985.11 Johansson, 1980, Thresholds of mechanosensitive afferents in the human hand as measured with von Frey hairs, Brain Res., 184, 343, 10.1016/0006-8993(80)90803-3 Lu, 2013, Somatosensory profiling of intra-oral capsaicin and menthol in healthy subjects, Eur. J. Oral Sci., 121, 29, 10.1111/eos.12014 Rolke, 2006, Quantitative sensory testing: a comprehensive protocol for clinical trials, Eur. J. Pain Lond. Engl., 10, 77, 10.1016/j.ejpain.2005.02.003 Baumgärtner, 2002, Neurogenic hyperalgesia versus painful hypoalgesia: two distinct mechanisms of neuropathic pain, Pain, 96, 141, 10.1016/S0304-3959(01)00438-9 Brouwers, 2009, Persistent neuropathy after treatment with cisplatin and oxaliplatin, Acta Oncol. Stockh. Swed., 48, 832, 10.1080/02841860902806609 Kokotis, 2016, Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study, Clin. Colorectal Cancer., 10.1016/j.clcc.2016.02.009 Park, 2011, Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility, Oncol., 16, 708, 10.1634/theoncologist.2010-0248 André, 2004, Oxaliplatin, Fluorouracil, and Leucovorin as adjuvant treatment for colon cancer, N. Engl. J. Med., 350, 2343, 10.1056/NEJMoa032709 Beijers, 2014, A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration, Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer., 22, 1999 Abad, 2017, Genotype-based selection of treatment for patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. Boyette-Davis, 2012, Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 18, 3180, 10.1158/1078-0432.CCR-12-0205 Sereno, 2017, Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy, BMC Cancer., 17, 63, 10.1186/s12885-016-3031-5